[go: up one dir, main page]

SE9503380D0 - Protein derivatives - Google Patents

Protein derivatives

Info

Publication number
SE9503380D0
SE9503380D0 SE9503380A SE9503380A SE9503380D0 SE 9503380 D0 SE9503380 D0 SE 9503380D0 SE 9503380 A SE9503380 A SE 9503380A SE 9503380 A SE9503380 A SE 9503380A SE 9503380 D0 SE9503380 D0 SE 9503380D0
Authority
SE
Sweden
Prior art keywords
factor
biocompatible polymer
relates
protein derivatives
adsorbent
Prior art date
Application number
SE9503380A
Other languages
English (en)
Inventor
Johanna Dalborg
Helena Sandberg
Anna-Lisa Smeds
Eva Aakerblom
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20399642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9503380(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9503380A priority Critical patent/SE9503380D0/sv
Publication of SE9503380D0 publication Critical patent/SE9503380D0/sv
Priority to DE69625085T priority patent/DE69625085T2/de
Priority to US09/029,672 priority patent/US6048720A/en
Priority to CA2231801A priority patent/CA2231801C/en
Priority to ES02013607T priority patent/ES2236396T3/es
Priority to NZ319322A priority patent/NZ319322A/en
Priority to DE69634373T priority patent/DE69634373T2/de
Priority to EP96932915A priority patent/EP0871649B1/en
Priority to PCT/SE1996/001215 priority patent/WO1997011957A1/en
Priority to PT96932915T priority patent/PT871649E/pt
Priority to PT02013613T priority patent/PT1258497E/pt
Priority to ES02013613T priority patent/ES2238522T3/es
Priority to ZA968139A priority patent/ZA968139B/xx
Priority to DK96932915T priority patent/DK0871649T3/da
Priority to EP02013613A priority patent/EP1258497B1/en
Priority to AT02013607T priority patent/ATE283351T1/de
Priority to EP02013607A priority patent/EP1260582B1/en
Priority to DK02013607T priority patent/DK1260582T3/da
Priority to HU9901203A priority patent/HU221208B1/hu
Priority to ES96932915T priority patent/ES2187676T3/es
Priority to PT02013607T priority patent/PT1260582E/pt
Priority to AU71517/96A priority patent/AU706246B2/en
Priority to AT02013613T priority patent/ATE289321T1/de
Priority to DK02013613T priority patent/DK1258497T3/da
Priority to JP51336397A priority patent/JP3911023B2/ja
Priority to DE69633952T priority patent/DE69633952T2/de
Priority to BR9610695A priority patent/BR9610695A/pt
Priority to PL96325958A priority patent/PL185821B1/pl
Priority to AT96932915T priority patent/ATE228531T1/de
Priority to NO19981408A priority patent/NO321096B1/no
Priority to NO20051950A priority patent/NO20051950L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Polyamides (AREA)
SE9503380A 1995-09-29 1995-09-29 Protein derivatives SE9503380D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE9503380A SE9503380D0 (sv) 1995-09-29 1995-09-29 Protein derivatives
PL96325958A PL185821B1 (pl) 1995-09-29 1996-09-27 Sposób udoskonalania funkcji in-vivo zrekombinowanSposób udoskonalania funkcji in-vivo zrekombinowanego czynnika VIII SQego czynnika VIII SQ
AT96932915T ATE228531T1 (de) 1995-09-29 1996-09-27 Konjugate eines polypeptids und eines biologisch verträglichem polymer
DK96932915T DK0871649T3 (da) 1995-09-29 1996-09-27 Konjugater af et polypeptid og en biokompatibel polymer
EP02013607A EP1260582B1 (en) 1995-09-29 1996-09-27 Conjugates of factor IX and a biocompatible polymer
CA2231801A CA2231801C (en) 1995-09-29 1996-09-27 Conjugates of a polypeptide and a biocompatible polymer
ES02013607T ES2236396T3 (es) 1995-09-29 1996-09-27 Conjugados de factor ixy un polimero biocompatible.
NZ319322A NZ319322A (en) 1995-09-29 1996-09-27 Conjugates of factor viii and a biopolymer
DE69634373T DE69634373T2 (de) 1995-09-29 1996-09-27 Verfahren zur Herstellung von Konjugaten vom Faktor VIII mit einem biologisch verträglichen Polymer
EP96932915A EP0871649B1 (en) 1995-09-29 1996-09-27 Conjugates of a polypeptide and a biocompatible polymer
PCT/SE1996/001215 WO1997011957A1 (en) 1995-09-29 1996-09-27 Conjugates of a polypeptide and a biocompatible polymer
PT96932915T PT871649E (pt) 1995-09-29 1996-09-27 Conjugados de um polipeptideo e de um polimero biocompativel
PT02013613T PT1258497E (pt) 1995-09-29 1996-09-27 Conjugados de factor viii e um polimero biocompativel
ES02013613T ES2238522T3 (es) 1995-09-29 1996-09-27 Metodo para preparar conjugados del factor viii y un polimero biocompatible.
ZA968139A ZA968139B (en) 1995-09-29 1996-09-27 Protein derivatives
DE69625085T DE69625085T2 (de) 1995-09-29 1996-09-27 Konjugate eines polypeptids und eines biologisch verträglichem polymer
EP02013613A EP1258497B1 (en) 1995-09-29 1996-09-27 Method to prepare conjugates of factor VIII and a biocompatible polymer
AT02013607T ATE283351T1 (de) 1995-09-29 1996-09-27 Konjugate von faktor ix und einem biologisch verträglichen polymer
US09/029,672 US6048720A (en) 1995-09-29 1996-09-27 Conjugates of a polypeptide and a biocompatible polymer
DK02013607T DK1260582T3 (da) 1995-09-29 1996-09-27 Konjugater af faktor IX og en bioforligelig polymer
HU9901203A HU221208B1 (en) 1995-09-29 1996-09-27 Conjugates of a polypeptide and a biocompatible polymer
ES96932915T ES2187676T3 (es) 1995-09-29 1996-09-27 Conjugados de un polipeptido y un polimero biocompatible.
PT02013607T PT1260582E (pt) 1995-09-29 1996-09-27 Conjugados de factor ix e um polimero biocompativel
AU71517/96A AU706246B2 (en) 1995-09-29 1996-09-27 Conjugates of a polypeptide and a biocompatible polymer
AT02013613T ATE289321T1 (de) 1995-09-29 1996-09-27 Verfahren zur herstellung von konjugaten vom faktor viii mit einem biologisch verträglichen polymer
DK02013613T DK1258497T3 (da) 1995-09-29 1996-09-27 Fremgangsmåde til fremstilling af konjugater af faktor VIII og en biokompatibel polymer
JP51336397A JP3911023B2 (ja) 1995-09-29 1996-09-27 ポリペプチドと生体適合性ポリマーとのコンジュゲート
DE69633952T DE69633952T2 (de) 1995-09-29 1996-09-27 Konjugate von Faktor IX und einem biologisch verträglichen Polymer
BR9610695A BR9610695A (pt) 1995-09-29 1996-09-27 Polipeptideo conjugado em um polipeptídeo e um polímero biocompatível e do fator viii do fator de von willebrand ou um combinação destes e utilização dos mesmos
NO19981408A NO321096B1 (no) 1995-09-29 1998-03-27 Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet
NO20051950A NO20051950L (no) 1995-09-29 2005-04-21 Konjugater av et polypeptid og en biokompatibel polymer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9503380A SE9503380D0 (sv) 1995-09-29 1995-09-29 Protein derivatives

Publications (1)

Publication Number Publication Date
SE9503380D0 true SE9503380D0 (sv) 1995-09-29

Family

ID=20399642

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9503380A SE9503380D0 (sv) 1995-09-29 1995-09-29 Protein derivatives

Country Status (18)

Country Link
US (1) US6048720A (sv)
EP (3) EP1258497B1 (sv)
JP (1) JP3911023B2 (sv)
AT (3) ATE283351T1 (sv)
AU (1) AU706246B2 (sv)
BR (1) BR9610695A (sv)
CA (1) CA2231801C (sv)
DE (3) DE69625085T2 (sv)
DK (3) DK0871649T3 (sv)
ES (3) ES2236396T3 (sv)
HU (1) HU221208B1 (sv)
NO (2) NO321096B1 (sv)
NZ (1) NZ319322A (sv)
PL (1) PL185821B1 (sv)
PT (3) PT871649E (sv)
SE (1) SE9503380D0 (sv)
WO (1) WO1997011957A1 (sv)
ZA (1) ZA968139B (sv)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
WO1999055377A2 (en) * 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
PT1820516E (pt) 1999-02-22 2013-10-31 Baxter Int Novas formulações de factor viii isentas de albumina
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
IT1318484B1 (it) * 2000-04-21 2003-08-25 Univ Roma Derivati di colina per il trattamento della malattia di alzheimer.
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20020120109A1 (en) * 2000-07-07 2002-08-29 Samokhin Gennady P. Biologically active proteins
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP2010209109A (ja) * 2001-06-25 2010-09-24 Regents Of The Univ Of Michigan 抗微生物ナノエマルジョンの組成物および方法
BR0211071A (pt) * 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
ES2466024T3 (es) * 2001-10-10 2014-06-09 Ratiopharm Gmbh Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
SE0104186D0 (sv) * 2001-12-12 2001-12-12 Darcy Birse Method and device
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
US20030149246A1 (en) * 2002-02-01 2003-08-07 Russell John C. Macromolecular conjugates and processes for preparing the same
US20050153416A1 (en) * 2002-03-02 2005-07-14 Nikolaos Dimoudis Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
EP2353611B1 (en) * 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
US7217794B2 (en) * 2003-04-02 2007-05-15 Daiamed, Inc. Compounds and methods for treatment of thrombosis
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20080146782A1 (en) * 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
HUE043911T2 (hu) * 2003-05-23 2019-09-30 Nektar Therapeutics Két PEG láncot tartalmazó PEG származékok
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2005055950A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20050171002A1 (en) * 2004-02-03 2005-08-04 Mohanty Dillip K. Polyoxyalkylene compound and method for making
ATE489105T1 (de) 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
ZA200609930B (en) * 2004-06-08 2009-01-28 Alza Corp Macromolecular peg conjucates by four-component condensation
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
KR101146160B1 (ko) 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
PL1797112T3 (pl) * 2004-09-29 2011-04-29 The Administrators Of The Tulane Educational Fund Inhibitory wirusa zapalenia wątroby typu C
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
AU2016203693B2 (en) * 2004-11-12 2018-08-23 Bayer Healthcare Llc Site-directed modification of FVIII
HRP20070268B1 (hr) * 2004-11-12 2018-04-20 Bayer Healthcare Llc Ciljana modifikacija faktora viii
CA2586909A1 (en) * 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
AU2012203813B2 (en) * 2004-11-12 2013-10-24 Bayer Healthcare Llc Site-directed modification of FVIII
AU2013203348B2 (en) * 2004-11-12 2016-03-03 Bayer Healthcare Llc Site-directed modification of FVIII
BRPI0519562A2 (pt) * 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (en) * 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US7395967B2 (en) * 2005-07-21 2008-07-08 University Of Washington Methods and systems for counterbalancing a scanning beam device
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
NZ572050A (en) 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
EP2097096B1 (en) 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
US8507653B2 (en) * 2006-12-27 2013-08-13 Nektar Therapeutics Factor IX moiety-polymer conjugates having a releasable linkage
WO2008082669A2 (en) 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
JP5401446B2 (ja) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
CA2690218C (en) * 2007-06-13 2017-02-28 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
DK2176296T3 (da) 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
GB2467700A (en) * 2007-11-09 2010-08-11 Baxter Int Modified recombinant Factor VIII and von Willebrand Factor and methods of use
DK2247620T3 (en) 2008-01-31 2016-08-22 Genentech Inc ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
EP2626079A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjungated factor VIII molecules
CA2726942A1 (en) 2008-06-04 2009-12-10 Bayer Healthcare Llc Fviii muteins for treatment of von willebrand disease
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
PL2349341T3 (pl) * 2008-10-15 2014-03-31 Baxalta Inc Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych
WO2010062768A1 (en) * 2008-11-03 2010-06-03 Bayer Healthcare Llc Method for the treatment of hemophilia
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
US9974844B2 (en) 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
PT3326643T (pt) 2009-12-06 2021-07-12 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos de fator viii-fc e métodos para a sua utilização
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
ES2899848T3 (es) 2012-01-12 2022-03-15 Bioverativ Therapeutics Inc Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
PT3564260T (pt) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
BR112014025737A2 (pt) * 2012-04-16 2017-07-04 Cantab Biopharmaceuticals Patents Ltd método para administrar um agente terapêutico, método para prevenir a entrada de um agente terapêutico, método para modular a velocidade de liberação de um agente terapêutico, agente terapêutico, formas de dosagem, método de tratamento de uma doença e kit de partes
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN105392495A (zh) 2013-06-28 2016-03-09 比奥根Ma公司 具有xten的凝血酶可裂解连接子和其用途
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
AU2015283822B2 (en) 2014-07-02 2019-10-03 CSL Behring Lengnau AG Modified von willebrand factor
AU2015320678B2 (en) 2014-09-23 2021-07-22 Genentech, Inc. Method of using anti-CD79b immunoconjugates
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
SG11201708754XA (en) 2015-05-22 2017-12-28 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
EA202092049A1 (ru) 2015-11-13 2020-11-10 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
SG10202106307UA (en) 2015-11-13 2021-07-29 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
KR20180098404A (ko) 2016-01-07 2018-09-03 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 폰 빌레브란트 인자
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
KR102175878B1 (ko) 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
JP7252890B2 (ja) 2016-11-11 2023-04-05 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
KR20220147721A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
US12161760B2 (en) 2018-04-04 2024-12-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
MX2021000582A (es) 2018-07-16 2021-04-12 Baxalta Inc Terapia genica de hemofilia a mediante el uso de vectores virales que codifican variantes del factor viii (fviii) recombinantes con mayor expresion.
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN114981299A (zh) 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
EP4171657A1 (en) 2020-06-24 2023-05-03 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
EP4392443A1 (en) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Optimized factor viii genes
JP2024537797A (ja) 2021-09-30 2024-10-16 バイオベラティブ セラピューティクス インコーポレイテッド 低下した免疫原性を有する第ｖｉｉｉ因子ポリペプチドをコードする核酸
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE3717210C2 (de) * 1987-05-22 1993-11-25 Diagen Inst Molekularbio Verfahren zur Modifizierung von Nukleinsäuren
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates

Also Published As

Publication number Publication date
EP1258497A3 (en) 2002-11-27
CA2231801C (en) 2010-07-27
EP1260582A1 (en) 2002-11-27
JPH11513378A (ja) 1999-11-16
PT1260582E (pt) 2005-03-31
DK1258497T3 (da) 2005-06-06
DE69625085T2 (de) 2003-07-17
AU7151796A (en) 1997-04-17
ATE283351T1 (de) 2004-12-15
HUP9901203A2 (hu) 1999-07-28
EP1258497B1 (en) 2005-02-16
BR9610695A (pt) 1999-07-06
EP1260582B1 (en) 2004-11-24
EP0871649A1 (en) 1998-10-21
ZA968139B (en) 1997-05-29
ES2238522T3 (es) 2005-09-01
EP0871649B1 (en) 2002-11-27
HUP9901203A3 (en) 2000-02-28
DK0871649T3 (da) 2003-03-24
US6048720A (en) 2000-04-11
PT871649E (pt) 2003-04-30
ATE289321T1 (de) 2005-03-15
NO981408L (no) 1998-03-27
ATE228531T1 (de) 2002-12-15
DE69633952D1 (de) 2004-12-30
EP1258497A2 (en) 2002-11-20
PL325958A1 (en) 1998-08-17
WO1997011957A1 (en) 1997-04-03
NO20051950L (no) 1998-03-27
DE69634373D1 (de) 2005-03-24
DK1260582T3 (da) 2005-03-29
DE69633952T2 (de) 2006-03-02
DE69625085D1 (de) 2003-01-09
JP3911023B2 (ja) 2007-05-09
ES2236396T3 (es) 2005-07-16
CA2231801A1 (en) 1997-04-03
NO981408D0 (no) 1998-03-27
NO321096B1 (no) 2006-03-13
DE69634373T2 (de) 2005-12-29
PT1258497E (pt) 2005-06-30
NZ319322A (en) 1998-08-26
PL185821B1 (pl) 2003-08-29
ES2187676T3 (es) 2003-06-16
AU706246B2 (en) 1999-06-10
HU221208B1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
SE9503380D0 (sv) Protein derivatives
CA2150925A1 (en) Improved synthesis of polymer bio-active conjugates
ATE236656T1 (de) Eingeschränktes multifunktionelles reagens zur oberflächenmodifikation
AU645747B2 (en) A novel antibody delivery system for biological response modifiers
EA200001111A1 (ru) КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
AU7366687A (en) Coupling agents for radiolabeling proteins
BR9509001A (pt) Proteína que objetiva virions de HIV com base em moléculas de fusão HIV-1 VPR
FR12C0059I1 (sv)
DE50014571D1 (de) Träger-pharmaka-konjugate
NO166267C (no) Konjugat av et maalsoekende biologisk aktivt molekyl og en forbindelse inneholdende spormerkende metall, samt diagnostisk preparat inneholdende konjugatet.
AU6264686A (en) Antibody complexes of hapten-modified diagnostic or therapeutic agents
DE3751574D1 (de) Diagnose- und heilmittel-antikörperkonjugate.
ATE324119T1 (de) Verwendung von saccharid-konjugaten
PT973806E (pt) Modificacao de proteinas com locais protegidos
MX2007007703A (es) Ligandos de afinidad de union a anticuerpos.
FI893428A7 (sv) Eliminering av toxiska egenskaper in vitro och in vivo hos TNF-a medelst monoklonala antikroppar och fragment härledda från dessa
IE820023L (en) Antitumour immunoglobulin conjugates.
AU3784601A (en) Oligosaccharide supports for e.g. removal of antibodies from blood
WO1993020852A3 (en) Macrocyclic chelating agents, chelates and conjugates thereof
EA200100311A1 (ru) Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств
RU95104325A (ru) Коньюгаты антител с улучшенными свойствами
RU93055877A (ru) Вещество усиливающее экскрецию желчной кислоты